APTOCROM Inc.
Financials
Valuation Metrics
APTOCROM Inc.'s Market Cap is ₩276B. At end of 2025 it was ₩729B. Ranked #2151 of 2,421 in KR market (top 89%), #1394 of 1,640 on KOSDAQ (top 85%), #216 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 94%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 27.62B KRW | KR#2,151/2,421 Sec#216/231 |
| Revenue | 10.78B KRW | KR#2,280/2,421 Sec#174/231 |
| Net Income | 38.26B KRW | KR#498/2,421 Sec#31/231 |
| Total Assets | 379.47B KRW | KR#902/2,421 Sec#53/231 |
| Net Assets | 361.63B KRW | KR#642/2,421 Sec#41/231 |
| Employees | 15 | KR#2,274/2,421 Sec#214/231 |
| Value | ||
| P/E | 0.72x | KR#7/2,421 Sec#1/231 |
| P/B | 0.08x | KR#10/2,421 Sec#1/231 |
| P/S | 2.56x | KR#1,923/2,421 Sec#113/231 |
| FCF Yield | 8.77% | KR#654/2,421 Sec#31/231 |
| Profitability | ||
| ROE | 10.58% | KR#569/2,421 Sec#39/231 |
| ROA | 10.08% | KR#269/2,421 Sec#20/231 |
| Op. Margin | -12.77% | KR#2,038/2,421 Sec#136/231 |
| Revenue Growth | -16.59% | KR#2,075/2,421 Sec#189/231 |
| Financial Health | ||
| Debt Ratio | 4.93% | KR#35/2,421 Sec#10/231 |
| Total Debt | 8.54B KRW | KR#1,675/2,421 Sec#153/231 |
| FCF | 2.42B KRW | KR#1,054/2,421 Sec#73/231 |
| Cash | 4.09B KRW | KR#2,076/2,421 Sec#192/231 |
| Current Ratio | 5.63x | KR#241/2,421 Sec#45/231 |
| Performance | ||
| 1Y Return | -74.35% | KR#2,327/2,421 Sec#221/231 |
| 1M Return | -1.62% | KR#1,434/2,421 Sec#109/231 |
| From 52W High | -76.28% | KR#2,307/2,421 Sec#205/231 |
| 1Y MDD | -78.23% | KR#2,265/2,421 Sec#203/231 |
| Trading | ||
| Volume | 1,084 shares | KR#2,320/2,421 Sec#224/231 |
| Trading Value | 2.0M KRW | KR#2,363/2,421 Sec#226/231 |
| Foreign Own. | 0.00% | KR—/2,421 Sec—/231 |
| Per Share | ||
| EPS | 2,529 KRW | KR#390/2,421 Sec#26/231 |
| BPS | 23,898 KRW | KR#472/2,421 Sec#32/231 |
Company Info
This company, established in 1988 and listed on KOSDAQ in 2009, operates pharmaceutical distribution and real estate/equipment leasing, holding three unlisted subsidiaries. Its subsidiary Aprogen I&C specializes in special nuclear power plant insulation and foamed glass insulation materials. The company responds to increasing well-being demand from an aging population and anticipates rising foamed glass insulation material demand from nuclear power plant exports and a shipbuilding boom, enhancing its business competitiveness. Aptokrom was established in 1998 and is headquartered in Seongnam-si, Gyeonggi-do.